<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JFM</journal-id>
<journal-id journal-id-type="hwp">spjfm</journal-id>
<journal-title>Journal of Feline Medicine and Surgery</journal-title>
<issn pub-type="ppub">1098-612X</issn>
<issn pub-type="epub">1532-2750</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1098612X12471526</article-id>
<article-id pub-id-type="publisher-id">10.1177_1098612X12471526</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Pharmacokinetics of imipenem after intravenous, intramuscular and subcutaneous administration to cats</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Albarellos</surname><given-names>Gabriela A</given-names></name>
<xref ref-type="aff" rid="aff1-1098612X12471526">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Denamiel</surname><given-names>Graciela A</given-names></name>
<xref ref-type="aff" rid="aff2-1098612X12471526">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Montoya</surname><given-names>Laura</given-names></name>
<xref ref-type="aff" rid="aff1-1098612X12471526">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Quaine</surname><given-names>Pamela C</given-names></name>
<xref ref-type="aff" rid="aff1-1098612X12471526">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lupi</surname><given-names>Martín P</given-names></name>
<xref ref-type="aff" rid="aff1-1098612X12471526">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Landoni</surname><given-names>María F</given-names></name>
<xref ref-type="aff" rid="aff3-1098612X12471526">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-1098612X12471526"><label>1</label>Department of Pharmacology, School of Veterinary Science, University of Buenos Aires, Buenos Aires, Argentina</aff>
<aff id="aff2-1098612X12471526"><label>2</label>Department of Microbiology, School of Veterinary Science, University of Buenos Aires, Buenos Aires, Argentina</aff>
<aff id="aff3-1098612X12471526"><label>3</label>Department of Pharmacology, School of Veterinary Science, University of La Plata, Buenos Aires, Argentina</aff>
<author-notes>
<corresp id="corresp1-1098612X12471526">Gabriela Albarellos MV, PhD, Department of Pharmacology, School of Veterinary Science, University of Buenos Aires, Chorroarin 280 (1427), Buenos Aires, Argentina Email: <email>albarell@fvet.uba.ar</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>15</volume>
<issue>6</issue>
<fpage>483</fpage>
<lpage>487</lpage>
<permissions>
<copyright-statement>© ISFM and AAFP 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">International Society of Feline Medicine and American Association of Feline Practitioners</copyright-holder>
</permissions>
<abstract>
<p>The study describes the pharmacokinetics and predicted efficacy of imipenem after intravenous (IV), intramuscular (IM) and subcutaneous (SC) administration to five adult cats at a dose of 5 mg/kg. Susceptibility to imipenem [minimum inhibitory concentration (MIC)] was determined for antimicrobial resistant <italic>Escherichia coli</italic> (n = 13) and staphylococci (n = 3) isolated from domestic cat infections (urinary system, skin and conjunctiva). Maximum plasma concentrations of imipenem were 13.45 µg/ml (IV), 6.47 µg/ml (IM) and 3.83 µg/ml (SC). Bioavailability was 93.18% (IM) and 107.90% (SC). Elimination half-lives for IV, IM and SC administration were 1.17, 1.44 and 1.55 h, respectively. All tested bacteria were susceptible to imipenem; MIC values were 0.03 µg/ml for <italic>Staphylococcus</italic> species and &lt;0.25–0.5 µg/ml for <italic>E coli</italic>. Mean imipenem concentrations remained above a MIC of 0.5 µg/ml for approximately 4 h (IV and IM) and 9 h (SC). Imipenem would be predicted to be effective for the treatment of antimicrobial resistant bacterial infections in cats at a dosage of 5 mg/kg every 6–8 h (IV, IM), or longer for the SC route. However, clinical trials are mandatory to establish its efficacy and proper dosing.</p>
</abstract>
</article-meta>
</front>
<body>
<sec id="section1-1098612X12471526" sec-type="intro">
<title>Introduction</title>
<p>Imipenem (N-formimidoyl thienamycin) is a beta-lactam antibiotic of the carbapenem class with a broad spectrum of activity that includes most pathogenic bacteria. It is highly active against aerobic and anaerobic Gram-positive and Gram-negative bacteria [<italic>Staphylococcus</italic> species (with the exception of methicillin-resistant strains), <italic>Streptococcus</italic> species, Enterobacteriaceae and <italic>Pseudomonas aeruginosa</italic>] and is resistant to many beta-lactamases.<sup><xref ref-type="bibr" rid="bibr1-1098612X12471526">1</xref></sup> Susceptible bacteria from human isolates have a minimum inhibitory concentration (MIC) break-point of ≤4 µg/ml, which could be an approximate reference for veterinary pathogens.<sup><xref ref-type="bibr" rid="bibr2-1098612X12471526">2</xref></sup></p>
<p>Beta-lactams have a time-dependent antibacterial efficacy; the cumulative percentage of the dose interval that drug concentration exceeds the MIC at steady state pharmacokinetic conditions (T&gt;MIC) is the best predictor of efficacy. As carbapenems have greater bactericidal activity and a longer post-antibiotic effect than other beta-lactams, the T&gt;MIC may be as low as 20–40% of the dose interval.<sup><xref ref-type="bibr" rid="bibr3-1098612X12471526">3</xref>,<xref ref-type="bibr" rid="bibr4-1098612X12471526">4</xref></sup> However, greater T&gt;MIC is indicated to decrease the risk of resistance development.<sup><xref ref-type="bibr" rid="bibr5-1098612X12471526">5</xref></sup></p>
<p>In kidney, a dihydropeptidase hydrolyses imipenem to an inactive nephrotoxic metabolite. Combination with cilastatin (1:1), a dihydropeptidase inhibitor that lacks antibacterial activity, inhibits renal metabolism. Cilastatin increases its elimination half-life and allows its renal elimination as an active drug resulting in higher urine concentrations.<sup><xref ref-type="bibr" rid="bibr1-1098612X12471526">1</xref></sup></p>
<p>The efficacy of imipenem for treating hospital-acquired infections in humans caused by multi-resistant Gram-negative bacteria, or mixed aerobic and anaerobic infections<sup><xref ref-type="bibr" rid="bibr1-1098612X12471526">1</xref></sup> is very high.</p>
<p>In veterinary medicine, imipenem is used for infections caused by bacteria resistant to other antimicrobials (especially <italic>P aeruginosa, Escherichia coli</italic> and <italic>Klebsiella pneumoniae</italic>), which are refractory to more commonly used agents.<sup><xref ref-type="bibr" rid="bibr6-1098612X12471526">6</xref>,<xref ref-type="bibr" rid="bibr7-1098612X12471526">7</xref></sup></p>
<p>Imipenem pharmacokinetic studies in domestic animals are scarce; they have only been described in dogs,<sup><xref ref-type="bibr" rid="bibr8-1098612X12471526">8</xref></sup> horses<sup><xref ref-type="bibr" rid="bibr9-1098612X12471526">9</xref></sup> and sheep.<sup><xref ref-type="bibr" rid="bibr10-1098612X12471526">10</xref></sup> To our knowledge, there are not reports in cats. The objective of the present study was to describe the pharmacokinetics and to predict efficacy based upon pharmacokinetic data of imipenem after intravenous (IV), intramuscular (IM) and subcutaneous (SC) administration to cats after single doses of 5 mg/kg.</p>
</sec>
<sec id="section2-1098612X12471526" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section3-1098612X12471526">
<title>Animals</title>
<p>Five adult mixed breed cats (one female and four males) weighing 5.54 ± 0.47 kg were assessed as healthy based on the results of physical examination, complete blood count, biochemical profile and urinalysis. Animals were housed in the University of Buenos Aires (UBA) Faculty of Veterinary Medicine facilities and allowed to acclimatize for 2 months before the experiments. Access to high quality dry food (Fit 32; Royal Canin) and water was ad libitum.</p>
<p>The study protocol was approved by the Institutional Animal Care and Use Committee, School of Veterinary, University of Buenos Aires, Argentina.</p>
</sec>
<sec id="section4-1098612X12471526">
<title>Dosage forms</title>
<p>A commercially available formulation of imipenem-cilastatin (Zienam IV Imipenem/Cilastatina Sódica; Merck Sharp &amp; Dohme) was used. Before administration, the powder was dissolved in sterile saline solution (0.9% NaCl) to a concentration of 25 mg/ml. Imipenem was administered IV, IM and SC at a dose of 5 mg/kg.</p>
</sec>
<sec id="section5-1098612X12471526">
<title>Experimental design</title>
<p>A three-period, three-treatment crossover design was used, such that each of the five cats received imipenen IV, IM and SC in a randomized sequence (Microsoft Office Excel). For IV administration, the dose was given over a 2 min period via a catheter placed in the cephalic vein. For the IM route, the dose was administered in the dorsal lumbar muscles, and for SC administration the dose was injected into the loose skin over the shoulders. Two-week intervals were allowed between each period.</p>
</sec>
<sec id="section6-1098612X12471526">
<title>Sampling procedures</title>
<p>Blood samples (0.7 ml) were collected via an aseptically placed cephalic catheter prior to drug administration at 0.083, 0.16, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10 and 12 h. Samples were placed immediately into tubes containing sodium heparin, mixed and placed on ice until plasma separation. Plasma was separated after centrifugation (15 min at 1500 <italic>g</italic>), stored at 4ºC and analyzed within 6 h of collection.</p>
</sec>
<sec id="section7-1098612X12471526">
<title>Plasma drug analysis</title>
<p>Plasma concentrations of imipenem were determined by use of microbiological assay<sup><xref ref-type="bibr" rid="bibr11-1098612X12471526">11</xref></sup> using <italic>Bacillus subtilis</italic> American Type Culture Collection (ATCC) 6633 as test microorganism. The lack of antimicrobial activity of cilastatin was verified by comparing the sizes of the zones of inhibition for standards concentration of imipenem with and without cilastatin. Standard curves were prepared in cat normal plasma between 0.05 and 25 µg/ml imipenem concentrations (Imipenem; Sigma-Aldrich) on the day of each study and stored at −4°C until sample analyzing (within 6 h of collection). The assay was linear from 0.05 to 25 µg/ml, with inter- and intra-assay variation of &lt;10% within this range. The limit of detection and quantification of the method were 0.05 µg/ml and 0.10 µg/ml, respectively. The lower limit of quantification (LLOQ) was the lower limit of concentration used in the pharmacokinetics analysis.</p>
<sec id="section8-1098612X12471526">
<title>Pharmacokinetic analysis</title>
<p>Pharmacokinetic analyses were performed with computer software (PCNonlin, SCI Software, v4). Initial estimates were determined using the residual method<sup><xref ref-type="bibr" rid="bibr12-1098612X12471526">12</xref></sup> and refitted by non-linear regression.</p>
<p>The number of exponents needed for IV, IM and SC administration data was determined by applying the Schwartz<sup><xref ref-type="bibr" rid="bibr13-1098612X12471526">13</xref></sup> and Akaike criterions,<sup><xref ref-type="bibr" rid="bibr14-1098612X12471526">14</xref></sup> and the residual distribution around the estimated concentrations.</p>
<p>Pharmacokinetic parameters were calculated using classic equations associated with compartmental analysis, except C<sub>max</sub> and T<sub>max</sub>, which were determined by visual inspection of plasma concentration time curves.<sup><xref ref-type="bibr" rid="bibr12-1098612X12471526">12</xref></sup></p>
</sec></sec>
<sec id="section9-1098612X12471526">
<title>Statistical analysis</title>
<p>All data are presented as medians and ranges. Main parameters [area under the curve<sub>(0–∞)</sub>, k, T<sub>½</sub>, mean residence time (MRT)] were statistically compared for the three administration routes, applying a non-parametric test for repeated measures (Friedman test) and a multiple comparison post-test (Dunn’s test). Pharmacokinetic parameters related to the absorption process [C<sub>max</sub>, T<sub>max</sub>, k<sub>a</sub>, T<sub>½(a)</sub>, mean absorption time (MAT) and F] were compared statistically by applying a non-parametric paired test (Wilcoxon test; GraphPad Prism, GraphPad Software). Values of <italic>P</italic> ≤0.05 were considered significant.</p>
</sec>
<sec id="section10-1098612X12471526">
<title>Susceptibility testing</title>
<p>The MIC of imipenem against thirteen strains of <italic>E coli</italic> (all resistant to ampicillin/sulbactam, first generation cephalosporins and trimethoprim/sulfamethoxazole; 12 resistant to gentamicin; 10 to ciprofloxacin; seven to ceftazidime; four to nitrofurantoin; and two resistant to tetracycline and chloramphenicol) and three strains of <italic>Staphylococcus</italic> species (all resistant to penicillin; two resistant to erythromycin, clindamycin and ciprofloxacin; and one resistant to tetracycline). All the strains were isolated from cat infections (urinary system, skin and conjunctiva). MICs were determined via broth macrodilution assay.<sup><xref ref-type="bibr" rid="bibr2-1098612X12471526">2</xref></sup> The isolates were provided by the diagnostic laboratory of the UBA Faculty of Veterinary Medicine.</p>
<p><italic>Escherichia coli</italic> ATCC 25922 (imipenem MIC 0.06–0.25 µg/ml) and <italic>Staphylococcus aureus</italic> ATCC 29213 (imipenem MIC 0.015–0.06 µg/ml) were used as quality control strains.</p>
</sec>
<sec id="section11-1098612X12471526">
<title>Pharmacokinetic/pharmacodynamic integration</title>
<p>Time above theT&gt;MIC for the three different administration routes was estimated by visual approximation from the plasma concentration versus time curve. The MIC value applied was the highest MIC obtained for the multi-resistant isolated microorganisms. T&gt;MIC was expressed as percentage of the recommended interdose interval in cats (6–8 h).<sup><xref ref-type="bibr" rid="bibr15-1098612X12471526">15</xref></sup></p>
</sec></sec>
<sec id="section12-1098612X12471526" sec-type="results">
<title>Results</title>
<p>No adverse effects were observed in any of the cats by physical examination. Also, there was no pain manifestation after imipenem SC administration.</p>
<p>Imipenem plasma concentration versus time curves after IV administration were best described by an open monocompartmental model in all the animals (<xref ref-type="fig" rid="fig1-1098612X12471526">Figure 1</xref>). <xref ref-type="table" rid="table1-1098612X12471526">Table 1</xref> shows the main pharmacokinetic parameters.</p>
<fig id="fig1-1098612X12471526" position="float">
<label>Figure 1</label>
<caption>
<p>Mean and 95% confidence interval imipenem plasma concentration–time profile after intravenous (IV) (▲), intramuscular (IM) (■) and subcutaneous (SC) (▼) administration at a dose of 5 mg/kg to cats (n = 5). MIC = minimum inhibitory concentration</p>
</caption>
<graphic xlink:href="10.1177_1098612X12471526-fig1.tif"/></fig>
<table-wrap id="table1-1098612X12471526" position="float">
<label>Table 1</label>
<caption>
<p>Median and range pharmacokinetic parameters of imipenem after intravenous, intramuscular and subcutaneous administration at single doses of 5 mg/kg to cats (n = 5) in a crossover design</p>
</caption>
<graphic alternate-form-of="table1-1098612X12471526" xlink:href="10.1177_1098612X12471526-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Pharmacokinetic parameter</th>
<th align="left">Intravenous administration<break/>median (range)</th>
<th align="left">Intramuscular administration<break/>median (range)</th>
<th align="left">Subcutaneous administration median (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC<sub>(0–∞)</sub> (µg.h/ml)</td>
<td>23.65 (20.39–31.72)</td>
<td>21.33 (20.60–22.09)</td>
<td>22.87 (15.49–27.31)</td>
</tr>
<tr>
<td>C<sub>p(0)</sub> (µg/ml)</td>
<td>13.47 (13.08–14.25)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Vss (l/kg)</td>
<td>0.37 (0.35–0.38)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>T<sub>max</sub> (h)</td>
<td>–</td>
<td>1.00 (0.50–2.00)</td>
<td>3.00 (1.50–3.00)<xref ref-type="table-fn" rid="table-fn1-1098612X12471526">*</xref></td>
</tr>
<tr>
<td>C<sub>max</sub> (µg/ml)</td>
<td>–</td>
<td>6.47 (4.77–7.47)</td>
<td>3.83 (3.10–4.80)<xref ref-type="table-fn" rid="table-fn1-1098612X12471526">*</xref></td>
</tr>
<tr>
<td>k<sub>a</sub> (h<sup>-1</sup>)</td>
<td>–</td>
<td>5.23 (2.17–6.71)</td>
<td>0.42 (0.29–0.71)<xref ref-type="table-fn" rid="table-fn1-1098612X12471526">*</xref></td>
</tr>
<tr>
<td>T<sub>½(a)</sub> (h)</td>
<td>–</td>
<td>0.13 (0.10–0.32)</td>
<td>1.63 (0.98–2.42)<xref ref-type="table-fn" rid="table-fn1-1098612X12471526">*</xref></td>
</tr>
<tr>
<td>MAT (h)</td>
<td>–</td>
<td>0.64 (0.49–0.90)</td>
<td>2.75 (2.30–3.52)<xref ref-type="table-fn" rid="table-fn1-1098612X12471526">*</xref></td>
</tr>
<tr>
<td>F (%)</td>
<td>–</td>
<td>93.18 (67.25–101.00)</td>
<td>107.90 (70.09–115.50)</td>
</tr>
<tr>
<td>Cl<sub>B</sub> (l/h.kg)</td>
<td>0.22 (0.16–0.24)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>k (h<sup>-1</sup>)</td>
<td>0.59 (0.43–0.66)<xref ref-type="table-fn" rid="table-fn1-1098612X12471526">*</xref></td>
<td>0.48 (0.38–0.65)</td>
<td>0.45 (0.29–0.49)<xref ref-type="table-fn" rid="table-fn1-1098612X12471526">*</xref></td>
</tr>
<tr>
<td>T<sub>½</sub> (h)</td>
<td>1.17 (1.06–1.62)<xref ref-type="table-fn" rid="table-fn1-1098612X12471526">*</xref></td>
<td>1.44 (1.07–1.82)</td>
<td>1.55 (1.41–2.40)<xref ref-type="table-fn" rid="table-fn1-1098612X12471526">*</xref></td>
</tr>
<tr>
<td>MRT (h)</td>
<td>1.65 (1.45–2.21)<xref ref-type="table-fn" rid="table-fn1-1098612X12471526">*</xref></td>
<td>2.29 (2.00–2.85)</td>
<td>4.34 (3.75–5.73)<xref ref-type="table-fn" rid="table-fn1-1098612X12471526">*</xref></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1098612X12471526">
<label>*</label>
<p>Significantly different (<italic>P</italic> &lt;0.05)</p></fn>
<fn id="table-fn2-1098612X12471526"><p>AUC <sub>(0-∞)</sub> = area under the plasma concentration vs time curve from 0 to infinite; C<sub>p (0) =</sub> plasma concentration at 0 time; Vss = volume of distribution; T<sub>max</sub> = time of maximum concentration; C<sub>max</sub> = maximum concentration; k<sub>a</sub> = absorption rate constant; T<sub>½ (a)</sub> = absorption half-life; MAT = mean absorption time; F = bioavailability; Cl<sub>B</sub> = body clearance; k = elimination rate constant; T<sub>½</sub> = elimination half-life; MRT = mean residence time</p></fn>
</table-wrap-foot></table-wrap>
<p>Imipenem administered IV was eliminated rapidly with a Cl<sub>B</sub> of 0.22 l/h/kg (range, 0.16–0.24), a T<sub>½</sub> of 1.17 h (range, 1.06–1.62 h) and a MRT of 1.65 h (range, 1.45–2.21 h). Imipenem plasma concentrations remained above the LLOQ for 6 h in 4/5 cats and for 8 h in the remaining cat.</p>
<p>Imipenem plasma disposition curves after IM and SC administration (<xref ref-type="fig" rid="fig1-1098612X12471526">Figure 1</xref>) were best described by a biexponential equation and explained by an open monocompartmental model with first order absorption in all the animals.</p>
<p>IM absorption was rapid, as reflected by the T<sub>max</sub> [1.00 h (range, 0.50–2.00 h)], the T<sub>½(a)</sub> [0.13 h (range, 0.10–0.30h)] and the MAT [0.64 h (range, 0.49–0.90 h)]. Bioavailability was high [93.18% (range, 67.25–101.00%)], reflecting the high extent of the process. C<sub>max</sub> was 6.47 µg/ml (range, 4.77–7.47 µg/ml); plasma concentrations remained above the LLOQ for 8 h in three cats and for 10 h in the remaining two cats.</p>
<p>Imipenem absorption after SC administration was, compared with IM administration, significantly slower (<italic>P</italic> ≤ 0.05), with no statistically significant differences on bioavailability. The delayed absorption after SC administration acts as limiting factor of the elimination process (flip/flop phenomenon) leading to a longer permanence of imipenem in plasma. This finding explains the smaller k [0.45 h (range, 0.29–0.49 h)], and longer T<sub>½</sub> [1.55 h (range, 1.41–2.40 h] and MRT [4.34 h (range, 3.75–5.73 h)] (<italic>P</italic> ≤ 0.05) (<xref ref-type="table" rid="table1-1098612X12471526">Table 1</xref>). Imipenem plasma concentrations were above the LLOQ for 12 h in three cats and for 10 h in the other two.</p>
<p>All the microorganisms tested were susceptible to imipenem. MIC values were 0.03 µg/ml for all <italic>Staphylococcus</italic> species and ≤0.5 µg/ml for the <italic>E coli</italic> strains.</p>
<p>For susceptible microorganisms with a MIC ≤0.5 µg/ml, T&gt;MIC was, for the IV and IM administration routes, approximately 4 h (ranging between 5 and 6 h and 4 and 6 h, respectively), representing around 50–67% of the inter-dose interval (8 h or 6 h, respectively). For the SC route, it was around 9 h (ranging between 8 and 10 h) exceeding 100% of the proposed inter-dose intervals.</p>
</sec>
<sec id="section13-1098612X12471526" sec-type="discussion">
<title>Discussion</title>
<p>Good correlation between microbiological assay and high performance liquid chromatography has been reported for imipenem determination.<sup><xref ref-type="bibr" rid="bibr8-1098612X12471526">8</xref>,<xref ref-type="bibr" rid="bibr16-1098612X12471526">16</xref></sup> In fact, this assay has been used for measuring imipenem concentrations in plasma and other biological fluids in a number of studies in animals and humans.<sup><xref ref-type="bibr" rid="bibr8-1098612X12471526">8</xref>,<xref ref-type="bibr" rid="bibr10-1098612X12471526">10</xref>,<xref ref-type="bibr" rid="bibr17-1098612X12471526">17</xref>
<xref ref-type="bibr" rid="bibr18-1098612X12471526"/><xref ref-type="bibr" rid="bibr19-1098612X12471526"/>–<xref ref-type="bibr" rid="bibr20-1098612X12471526">20</xref></sup></p>
<p>Imipenem plasma concentration profile and the main pharmacokinetic parameters after IV administration to cats were quite similar to, and in the range of, those described for humans and other domestic animals.<sup><xref ref-type="bibr" rid="bibr4-1098612X12471526">4</xref>,<xref ref-type="bibr" rid="bibr8-1098612X12471526">8</xref>
<xref ref-type="bibr" rid="bibr9-1098612X12471526"/>–<xref ref-type="bibr" rid="bibr10-1098612X12471526">10</xref>,<xref ref-type="bibr" rid="bibr17-1098612X12471526">17</xref>,<xref ref-type="bibr" rid="bibr18-1098612X12471526">18</xref>,<xref ref-type="bibr" rid="bibr20-1098612X12471526">20</xref>,<xref ref-type="bibr" rid="bibr21-1098612X12471526">21</xref></sup> However, in dogs administered an equivalent dose, plasma concentrations declined faster (T<sub>½</sub> 0.80 ± 0.23 h) than in cats [T<sub>½</sub> 1.17 h (range, 1.06–1.62 h)].<sup><xref ref-type="bibr" rid="bibr8-1098612X12471526">8</xref></sup></p>
<p>The estimated imipenem distribution value is in the order of that expected for a beta-lactam antibiotic. In fact, similar values are reported for other species.<sup><xref ref-type="bibr" rid="bibr4-1098612X12471526">4</xref>,<xref ref-type="bibr" rid="bibr8-1098612X12471526">8</xref>
<xref ref-type="bibr" rid="bibr9-1098612X12471526"/>–<xref ref-type="bibr" rid="bibr10-1098612X12471526">10</xref></sup> This value seems to indicate that imipenem distributes in the extracellular compartment (the site where most infections are localized).</p>
<p>Imipenem Cl<sub>B</sub> in cats [0.22 l/h/kg (range, 0.16–0.24 l/h/kg)] was slightly greater than the corresponding glomerular filtration rate (0.18 l/h/kg),<sup><xref ref-type="bibr" rid="bibr22-1098612X12471526">22</xref></sup> suggesting that imipenem (combined with cilastatin) is excreted mainly through renal tubular filtration with minimal involvement of other mechanisms, such as active tubular secretion. The same was proposed for humans, dogs, horses and sheep.<sup><xref ref-type="bibr" rid="bibr4-1098612X12471526">4</xref>,<xref ref-type="bibr" rid="bibr8-1098612X12471526">8</xref>
<xref ref-type="bibr" rid="bibr9-1098612X12471526"/>–<xref ref-type="bibr" rid="bibr10-1098612X12471526">10</xref></sup></p>
<p>After IM administration, imipenem absorption was faster and C<sub>max</sub> higher than after SC administration. Moreover, after SC administration imipenem remained in the plasma longer than after IM administration. These findings could be explained through the ‘flip-flop’ phenomenon, where terminal T<sub>½</sub> is reflecting the k<sub>a</sub> rather than the k. The same was observed in dogs.<sup><xref ref-type="bibr" rid="bibr8-1098612X12471526">8</xref></sup> This pharmacokinetic phenomenon would have clinical implications as it would prolong dosage intervals.</p>
<p>Bioavailability of imipenem after extravascular administration in cats was high (93.18% IM and 107.90% SC) without significant differences between administration routes. The same has been reported for other species, such as ovine (65.97% IM),<sup><xref ref-type="bibr" rid="bibr10-1098612X12471526">10</xref></sup> human (89% IM)<sup><xref ref-type="bibr" rid="bibr20-1098612X12471526">20</xref></sup> and canine (146% IM and 159% SC).<sup><xref ref-type="bibr" rid="bibr8-1098612X12471526">8</xref></sup> The almost complete absorption of the drug and its long permanence in plasma when administered extravascularly (especially SC) yield more desirable plasma concentration profiles than after IV administration. Barker et al<sup><xref ref-type="bibr" rid="bibr8-1098612X12471526">8</xref></sup> and Signs et al<sup><xref ref-type="bibr" rid="bibr20-1098612X12471526">20</xref></sup> reached similar conclusions when studying the pharmacokinetics of imipenem in dogs and humans respectively.</p>
<p>The isolation of bacteria resistant to many antimicrobials in patients treated previously with antibiotics is a common clinical finding.<sup><xref ref-type="bibr" rid="bibr23-1098612X12471526">23</xref>,<xref ref-type="bibr" rid="bibr24-1098612X12471526">24</xref></sup> All the bacteria strains isolated from cat infections (13 strains of <italic>E coli</italic> and three <italic>Staphylococcus</italic> species strains) tested in the present study showed resistance to commonly used antimicrobials (disk diffusion susceptibility test method<sup><xref ref-type="bibr" rid="bibr2-1098612X12471526">2</xref></sup>), but were highly susceptible to imipenem, with MIC values in the range of those found in other studies for the same bacterial species.<sup><xref ref-type="bibr" rid="bibr24-1098612X12471526">24</xref></sup></p>
<p>For carbapenems, a T&gt;MIC 30–40% of the dose interval has been established as optimal for bactericidal action.<sup><xref ref-type="bibr" rid="bibr3-1098612X12471526">3</xref>,<xref ref-type="bibr" rid="bibr4-1098612X12471526">4</xref></sup> In this study, this goal is achieved for up to 4 × MIC (2 µg/ml) in 6- or 8-h dose interval regimens.</p>
</sec>
<sec id="section14-1098612X12471526" sec-type="conclusions">
<title>Conclusions</title>
<p>Although the longest permanence of imipenem plasma concentrations is achieved after SC administration, efficacy will depend on MIC for the etiological agent. The superiority of the SC route would only be valid when the MIC of the organisms to be treated is relatively low (≤0.5 µg/ml). For microorganisms with higher MIC (MIC ≤4 µg/ml<sup><xref ref-type="bibr" rid="bibr2-1098612X12471526">2</xref></sup>) the IV or IM routes with an interval of 6–8 h is advisable.</p>
</sec>
</body>
<back>
<ack><p>The authors are indebted to Royal Canin, Argentina for the kind provision of the animal food.</p></ack>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This work was supported by a Research Project UBACyT (grant number 20020100100745, 2011-2014) of Secretaría de Ciencia y Técnica, Universidad de Buenos Aires, Argentina.</p></fn>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>The authors do not have any potential conflicts of interest to declare.</p></fn>
<fn fn-type="other">
<p><bold>Accepted:</bold> 26 November 2012</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1098612X12471526">
<label>1</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Prescott</surname><given-names>JF</given-names></name>
</person-group>. <article-title>Other beta-lactam antibiotics: Beta-lactamase inhibitors, carbapenems, and monobactams</article-title>. In: <person-group person-group-type="editor">
<name><surname>Giguère</surname><given-names>S</given-names></name>
<name><surname>Prescott</surname><given-names>JF</given-names></name>
<name><surname>Baggot</surname><given-names>JD</given-names></name><etal/>
</person-group> (eds). <source>Antimicrobial therapy in veterinary medicine</source>. <edition>4th ed</edition>. <publisher-loc>Oxford</publisher-loc>: <publisher-name>Blackwell Publishing</publisher-name>, <year>2006</year>, pp <fpage>159</fpage>–<lpage>170</lpage>.</citation>
</ref>
<ref id="bibr2-1098612X12471526">
<label>2</label>
<citation citation-type="book"><article-title>CLSI Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; approved standard</article-title>. <edition>3rd ed</edition>. Document M31-A3. <publisher-loc>Wayne, PA</publisher-loc>: <publisher-name>Clinical and Laboratory Standards Institute</publisher-name>, <year>2008</year>.</citation>
</ref>
<ref id="bibr3-1098612X12471526">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Adembri</surname><given-names>C</given-names></name>
<name><surname>Novelli</surname><given-names>A</given-names></name>
</person-group>. <article-title>Pharmacokinetic and pharmacodynamic parameters of antimicrobials. Potential for providing dosing regimens that are less vulnerable to resistance</article-title>. <source>Clin Pharmacokinet</source> <year>2009</year>; <volume>48</volume>: <fpage>517</fpage>–<lpage>528</lpage>.</citation>
</ref>
<ref id="bibr4-1098612X12471526">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mouton</surname><given-names>JW</given-names></name>
<name><surname>Touw</surname><given-names>DJ</given-names></name>
<name><surname>Alphonsus</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Comparative pharmacokinetics of the carbapenems. Clinical implications</article-title>. <source>Clin Pharmacokinet</source> <year>2000</year>; <volume>39</volume>: <fpage>185</fpage>–<lpage>201</lpage>.</citation>
</ref>
<ref id="bibr5-1098612X12471526">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drusano</surname><given-names>GL</given-names></name>
</person-group>. <article-title>Prevention of resistance: a goal for dose selection for antimicrobial agents</article-title>. <source>Clin Infect Dis</source> <year>2003</year>; <volume>36</volume> (<supplement>Suppl. 1</supplement>): <fpage>42</fpage>–<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr6-1098612X12471526">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Authier</surname><given-names>S</given-names></name>
<name><surname>Paquette</surname><given-names>D</given-names></name>
<name><surname>Labrecque</surname><given-names>O</given-names></name>
<etal/></person-group>. <article-title>Comparison of susceptibility to antimicrobials of bacterial isolates from companion animals in a veterinary diagnostic laboratory in Canada between 2 time points 10 years apart</article-title>. <source>Can Vet J</source> <year>2006</year>; <volume>47</volume>: <fpage>774</fpage>–<lpage>778</lpage>.</citation>
</ref>
<ref id="bibr7-1098612X12471526">
<label>7</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Guardabassi</surname><given-names>L</given-names></name>
<name><surname>Houser</surname><given-names>GA</given-names></name>
<name><surname>Frank</surname><given-names>LA</given-names></name>
<etal/></person-group>. <article-title>Guidelines for antimicrobial use in dogs and cats</article-title>. In: <person-group person-group-type="editor">
<name><surname>Guardabassi</surname><given-names>L</given-names></name>
<name><surname>Jensen</surname><given-names>LB</given-names></name>
<name><surname>Kruse</surname><given-names>H</given-names></name>
</person-group> (eds). <source>Guide to antimicrobial use in animals</source>. <publisher-loc>Oxford</publisher-loc>: <publisher-name>Blackwell Publishing</publisher-name>, <year>2008</year>, pp <fpage>183</fpage>–<lpage>206</lpage>.</citation>
</ref>
<ref id="bibr8-1098612X12471526">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barker</surname><given-names>CW</given-names></name>
<name><surname>Zhang</surname><given-names>W</given-names></name>
<name><surname>Sanchez</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Pharmacokinetics of imipenem in dogs</article-title>. <source>Am J Vet Res</source> <year>2003</year>; <volume>64</volume>: <fpage>694</fpage>–<lpage>699</lpage>.</citation>
</ref>
<ref id="bibr9-1098612X12471526">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Orsini</surname><given-names>JA</given-names></name>
<name><surname>Moate</surname><given-names>PJ</given-names></name>
<name><surname>Boston</surname><given-names>RC</given-names></name>
<etal/></person-group>. <article-title>Pharmacokinetics of imipenem-cilastatin following intravenous administration in healthy adult horses</article-title>. <source>J Vet Pharmacol Therap</source> <year>2005</year>; <volume>28</volume>: <fpage>355</fpage>–<lpage>361</lpage>.</citation>
</ref>
<ref id="bibr10-1098612X12471526">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abo El-Sooud</surname><given-names>K</given-names></name>
<name><surname>Khammas</surname><given-names>K</given-names></name>
<name><surname>Nadir Kadri</surname><given-names>M</given-names></name>
</person-group>. <article-title>Pharmacokinetics of imipenem in sheep with special reference to its hepato-renal effects</article-title>. <source>Chemotherapy</source> <year>2007</year>; <volume>53</volume>: <fpage>169</fpage>–<lpage>172</lpage>.</citation>
</ref>
<ref id="bibr11-1098612X12471526">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bennet</surname><given-names>JV</given-names></name>
<name><surname>Brodie</surname><given-names>JL</given-names></name>
<name><surname>Bennet</surname><given-names>EJ</given-names></name>
<etal/></person-group>. <article-title>Simplified accurate method for antibiotic assay of clinical specimens</article-title>. <source>Appl Microbiol</source> <year>1966</year>; <volume>14</volume>: <fpage>170</fpage>–<lpage>177</lpage>.</citation>
</ref>
<ref id="bibr12-1098612X12471526">
<label>12</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Gibaldi</surname><given-names>M</given-names></name>
<name><surname>Perrier</surname><given-names>D</given-names></name>
</person-group>. <article-title>Pharmacokinetics</article-title>. <edition>2nd ed</edition>. <publisher-loc>New York</publisher-loc>: <publisher-name>Marcel Dekker Inc</publisher-name>, <year>1982</year>.</citation>
</ref>
<ref id="bibr13-1098612X12471526">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schwartz</surname><given-names>G</given-names></name>
</person-group>. <article-title>Estimating the dimension of a model</article-title>. <source>Ann Stat</source> <year>1978</year>; <volume>6</volume>: <fpage>461</fpage>–<lpage>464</lpage>.</citation>
</ref>
<ref id="bibr14-1098612X12471526">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yamaoka</surname><given-names>K</given-names></name>
<name><surname>Nakagawa</surname><given-names>T</given-names></name>
<name><surname>Uno</surname><given-names>T</given-names></name>
</person-group>. <article-title>Application of Akaike’s information criterion (AIC) in the evaluation of linear pharmacokinetic equations</article-title>. <source>J Pharmacokinet Biopharm</source> <year>1978</year>; <volume>6</volume>: <fpage>165</fpage>–<lpage>175</lpage>.</citation>
</ref>
<ref id="bibr15-1098612X12471526">
<label>15</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Papich</surname><given-names>MG</given-names></name>
</person-group>. <article-title>Saunders handbook of veterinary drugs: small and large animal</article-title>. <edition>3rd ed</edition>. <publisher-loc>Missouri</publisher-loc>: <publisher-name>Elsevier Saunders</publisher-name>, <year>2011</year>, pp <fpage>378</fpage>–<lpage>380</lpage>.</citation>
</ref>
<ref id="bibr16-1098612X12471526">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gravallese</surname><given-names>DA</given-names></name>
<name><surname>Musson</surname><given-names>DG</given-names></name>
<name><surname>Pauliukonis</surname><given-names>LT</given-names></name>
<etal/></person-group>. <article-title>Determination of imipenem (N-formimidoyl thienamycin) in human plasma and urine by high-performance liquid chromatography, comparison with microbiological methodology and stability</article-title>. <source>J Chromatogr</source> <year>1984</year>; <volume>310</volume>: <fpage>71</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr17-1098612X12471526">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>MacGregor</surname><given-names>RR</given-names></name>
<name><surname>Gibson</surname><given-names>GA</given-names></name>
<name><surname>Bland</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Imipenem pharmacokinetics and body fluid concentrations in patients receiving high-dose treatment for serious infections</article-title>. <source>Antimicrob Agents Chemother</source> <year>1986</year>; <volume>29</volume>: <fpage>188</fpage>–<lpage>192</lpage>.</citation>
</ref>
<ref id="bibr18-1098612X12471526">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Norrby</surname><given-names>SR</given-names></name>
<name><surname>Björnegárd</surname><given-names>B</given-names></name>
<name><surname>Ferber</surname><given-names>F</given-names></name>
<etal/></person-group>. <article-title>Pharmacokinetics of imipenem in healthy volunteers</article-title>. <source>J Antimicrob Chemother</source> <year>1983</year>; <volume>12</volume> (<supplement>suppl D</supplement>): <fpage>109</fpage>–<lpage>124</lpage>.</citation>
</ref>
<ref id="bibr19-1098612X12471526">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Novelli</surname><given-names>A</given-names></name>
<name><surname>Adembri</surname><given-names>C</given-names></name>
<name><surname>Livi</surname><given-names>P</given-names></name>
<etal/></person-group>. <article-title>Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis</article-title>. <source>Clin Pharmacokinet</source> <year>2005</year>; <volume>44</volume>: <fpage>539</fpage>–<lpage>549</lpage>.</citation>
</ref>
<ref id="bibr20-1098612X12471526">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Signs</surname><given-names>SA</given-names></name>
<name><surname>Tan</surname><given-names>JS</given-names></name>
<name><surname>Salstrom</surname><given-names>SJ</given-names></name>
<etal/></person-group>. <article-title>Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration</article-title>. <source>Antimicrob Agents Chemother</source> <year>1992</year>; <volume>36</volume>: <fpage>1400</fpage>–<lpage>1403</lpage>.</citation>
</ref>
<ref id="bibr21-1098612X12471526">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drusano</surname><given-names>GL</given-names></name>
<name><surname>Standiford</surname><given-names>HC</given-names></name>
<name><surname>Bustamante</surname><given-names>C</given-names></name>
<etal/></person-group>. <article-title>Multiple-dose pharmacokinetics of imipenem-cilastatin</article-title>. <source>Antimicrobial Agents Chemother</source> <year>1984</year>; <volume>26</volume>: <fpage>715</fpage>–<lpage>721</lpage>.</citation>
</ref>
<ref id="bibr22-1098612X12471526">
<label>22</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Baggot</surname><given-names>JD</given-names></name>
</person-group>. <article-title>The physiological basis of veterinary clinical pharmacology</article-title>. <publisher-loc>London</publisher-loc>: <publisher-name>Blackwell Science</publisher-name>, <year>2001</year>, p <fpage>45</fpage>.</citation>
</ref>
<ref id="bibr23-1098612X12471526">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Black</surname><given-names>DM</given-names></name>
<name><surname>Rankin</surname><given-names>SC</given-names></name>
<name><surname>King</surname><given-names>LG</given-names></name>
</person-group>. <article-title>Antimicrobial therapy and aerobic bacteriologic culture patterns in canine intensive care unit patients: 74 dogs (January–June 2006)</article-title>. <source>J Vet Emerg Crit Care</source> <year>2009</year>; <volume>19</volume>: <fpage>489</fpage>–<lpage>495</lpage>.</citation>
</ref>
<ref id="bibr24-1098612X12471526">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gibson</surname><given-names>JS</given-names></name>
<name><surname>Morton</surname><given-names>JM</given-names></name>
<name><surname>Cobbold</surname><given-names>RN</given-names></name>
<etal/></person-group>. <article-title>Multidrug-resistant E coli and Enterobacter extraintestinal infections in 37 dogs</article-title>. <source>J Vet Intern Med</source> <year>2008</year>; <volume>22</volume>: <fpage>844</fpage>–<lpage>850</lpage>.</citation>
</ref></ref-list>
</back>
</article>